EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Molecular and structural insights into the 5‐HT 2C receptor as a therapeutic target for substance use disorders

Maleesha Ubhayarathna, Christopher J Langmead iD, Natalie A Diepenhorst, Gregory D Stewart iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16233 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, 2024. Written by Maleesha Ubhayarathna and 3 co-authors. Institution: Drug Discovery Biology and Neuroscience & Mental Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, Par…. Major MEDLINE topics: Receptor, Serotonin, 5-HT2C, Substance-Related Disorders. Cited 11 times so far (Crossref); 150 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Substance use disorder (SUD) is a chronic condition, with maintained abuse of a substance leading to physiological and psychological alterations and often changes in cognitive and social behaviours. Current therapies include psychotherapy coupled with medication; however, high relapse rates reveal the shortcomings of these therapies. The signalling, expression profile, and neurological function of the serotonin 2C receptor (5‐HT 2C receptor) make it a candidate of interest for the treatment of SUD. Recently, psychedelics, which broadly act at 5‐HT 2 receptors, have indicated potential for the treatment of SUD, implicating the 5‐HT 2C receptor. The modern psychedelic movement has rekindled interest in the 5‐HT 2C receptor, resulting in many new studies, especially structural analyses. This review explores the structural, molecular and cellular mechanisms governing 5‐HT 2C receptor function in the context of SUD. This provides the basis of the preclinical and clinical evidence for their role in SUD and highlights the potential for future exploration.

Subjects

MeSH terms (MEDLINE)

Receptor, Serotonin, 5-HT2CSubstance-Related DisordersHumansAnimalsSerotonin 5-HT2 Receptor AgonistsHallucinogens

Author keywords

5‐HT5‐HT2C receptorGPCRSUDscell signallingdrug discovery

Substances

Receptor, Serotonin, 5-HT2CSerotonin 5-HT2 Receptor AgonistsHallucinogens

Authors and institutions

  • Drug Discovery Biology and Neuroscience & Mental Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
  • ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
  • Neuromedicines Discovery Centre, Monash University, Parkville, Australia.

ORCID profiles: Christopher J Langmead, Gregory D Stewart

Cite

APA

Ubhayarathna, M., Langmead, C. J., Diepenhorst, N. A., & Stewart, G. D. (2024). Molecular and structural insights into the 5‐HT 2C receptor as a therapeutic target for substance use disorders. British Journal of Pharmacology. https://doi.org/10.1111/bph.16233

Vancouver

Ubhayarathna M, Langmead CJ, Diepenhorst NA, Stewart GD. Molecular and structural insights into the 5‐HT 2C receptor as a therapeutic target for substance use disorders. British Journal of Pharmacology. 2024. doi:10.1111/bph.16233

BibTeX
@article{Ubhayarathna2024,
  author = {Ubhayarathna, Maleesha and Langmead, Christopher J and Diepenhorst, Natalie A and Stewart, Gregory D},
  title = {Molecular and structural insights into the 5‐HT 2C receptor as a therapeutic target for substance use disorders},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16233}
}
Start for free →